- Home
- REVB vs PALI Comparison
REVB vs PALI Comparison
Compare REVB & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- PALI
- Stock Information
- Founded
- REVB 2020
- PALI 1996
- Country
- REVB United States
- PALI United States
- Employees
- REVB N/A
- PALI N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REVB Health Care
- PALI Health Care
- Exchange
- REVB Nasdaq
- PALI Nasdaq
- Market Cap
- REVB 5.4M
- PALI 5.6M
- IPO Year
- REVB N/A
- PALI N/A
- Fundamental
- Price
- REVB $0.40
- PALI $1.48
- Analyst Decision
- REVB
- PALI Strong Buy
- Analyst Count
- REVB 0
- PALI 2
- Target Price
- REVB N/A
- PALI $23.00
- AVG Volume (30 Days)
- REVB 6.8M
- PALI 897.4K
- Earning Date
- REVB 11-08-2024
- PALI 11-12-2024
- Dividend Yield
- REVB N/A
- PALI N/A
- EPS Growth
- REVB N/A
- PALI N/A
- EPS
- REVB N/A
- PALI N/A
- Revenue
- REVB N/A
- PALI N/A
- Revenue This Year
- REVB N/A
- PALI N/A
- Revenue Next Year
- REVB N/A
- PALI N/A
- P/E Ratio
- REVB N/A
- PALI N/A
- Revenue Growth
- REVB N/A
- PALI N/A
- 52 Week Low
- REVB $0.28
- PALI $1.38
- 52 Week High
- REVB $25.26
- PALI $22.35
- Technical
- Relative Strength Index (RSI)
- REVB 39.87
- PALI 37.09
- Support Level
- REVB $0.39
- PALI $1.61
- Resistance Level
- REVB $0.53
- PALI $2.59
- Average True Range (ATR)
- REVB 0.13
- PALI 0.27
- MACD
- REVB 0.00
- PALI -0.01
- Stochastic Oscillator
- REVB 7.54
- PALI 2.63
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.